The Pharmasyntez Group of Companies has received seven Marketing Authorizations in Ecuador for drug products for the treatment of diabetes mellitus, HIV and malignant neoplasms (chemotherapy drugs), which allows the importation and distribution of the drugs into the country.

The drug products will be manufactured at the Pharmasyntez-Nord and Pharmasyntez-Tymen sites and at the Irkutsk plant of Pharmasyntez JSC. The start of supplies to Ecuador is scheduled for the near future.

The Pharmasyntez Group of Companies currently has more than 100 drug products registered in the CIS countries and Latin America.

“Recently, the company has received Marketing Authorizations in the Dominican Republic for the supply of three antineoplastic drugs manufactured by Pharmasyntez-Nord. The entry into Ecuador was a new step for the company to increase its presence in the Latin American market. Currently, active work is also underway with other key countries in the region. We see potential for cooperation with Latin America, first of all, in a fairly large number of friendly countries that are part of it and with which we have historically developed constructive relations in the region.” – Nikita Punia, Executive Director of the Pharmasyntez Group of Companies, said.

It is worth reminding that in July 2023, Pharmasyntez-Nord Research and Manufacturing Complex, which is a part of the Pharmasyntez Group of Companies, has successfully passed the inspection by the Syrian Ministry of Health for GMP compliance and received an official authorization to supply manufactured drugs to the Syrian Arab Republic.